2018
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends In Immunology 2018, 39: 624-631. PMID: 29802087, PMCID: PMC6066429, DOI: 10.1016/j.it.2018.05.001.Peer-Reviewed Original ResearchConceptsAnti-PD therapyLong-term survival benefitAvailable treatment regimensFraction of respondersSurvival benefitTumor immunityTumor-immune interactionsAdvanced cancerTreatment regimensCancer immunotherapyTumor regressionTherapyAccurate tissueSuch treatmentAdaptive resistancePatientsMolecular mechanismsTrue resistanceImmunotherapyRegimensRight targetCancerRespondersImmunityAppropriate interpretation
2000
Vinorelbine and Gemcitabine Combinations in Advanced Non–Small-Cell Lung Cancer
Lilenbaum R, Herbst R. Vinorelbine and Gemcitabine Combinations in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2000, 2: 123-127. PMID: 14731322, DOI: 10.3816/clc.2000.n.024.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerLung cancerSmall cell lung cancerPoor performance statusTaxane-based regimensVinorelbine/gemcitabinePlatinum-based regimensSingle-agent activityTreatment of patientsOverall response rateNew chemotherapeutic agentsNonoverlapping toxicitiesGemcitabine combinationElderly patientsPerformance statusRandomized studyResponse rateWeekly scheduleChemotherapeutic agentsVinorelbineRegimensGemcitabinePatientsRegimen